Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi) ...

French company DNA Script will contribute its enzymatic DNA synthesis technologies, while Quantoom of Belgium will bring its ...

Unlike standard mRNA vaccines, self-amplifying mRNA vaccines instruct the body to make more mRNA and protein to boost the immune response.

Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19 Meiji Seika Pharma Co., Ltd. (Headquarters ...

While some of the initial zeal around localized vaccine production in Africa has waned since the height of the COVID-19 pandemic, efforts to bolster the continent’s immunization autonomy—especially | ...

With its focus on self-amplifying mRNA (SAM-RNA) technology and strategic partnerships, Arcturus aims to differentiate itself in the lucrative vaccine market while advancing its therapeutic pipeline.

announced today that it has received approval for a partial amendment to the manufacturing and marketing approval of "KOSTAIVE ® for Intramuscular Injection," a self-amplifying mRNA vaccine for ...

Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi) announced today that it has received approval for a partial amendment to the manufacturing and marketing ...